Developer docs
API playgroundTry for free, no card

Search company profiles

Supernus Pharmaceuticals

Full company profile

uuid00027a4

Namestring
Supernus Pharmaceuticals
Legal namestring
Supernus Pharmaceuticals, Inc.
Websiteurl
supernus.com
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Supernus Pharmaceuticals, Inc. is a publicly traded specialty biopharmaceutical company (NASDAQ: SUPN) headquartered in Rockville, Maryland, with more than 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases. The company develops, manufactures, and markets nine branded prescription products spanning five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, via Biogen collaboration), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia/sialorrhea (Myobloc). It sells primarily to U.S. specialty prescribers—neurologists, psychiatrists, and movement-disorder specialists—through dedicated specialty sales forces, while out-licensing international commercialization to other pharmaceutical partners.

The product franchise is anchored by a proprietary drug delivery and formulation technology platform that has produced ten marketed products, including own-brand launches (Qelbree, Trokendi XR, Oxtellar XR) and products developed for Shire/Takeda (Adderall XR, Intuniv, Mydayis) and United Therapeutics (Orenitram). Supernus has materially supplemented internal R&D through two acquisitions: Adamas Pharmaceuticals in November 2021 (~$450M) added GOCOVRI and Osmolex ER, and Sage Therapeutics in July 2025 (~$561–795M) added ZURZUVAE. Two Phase 2 pipeline candidates—SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy—are advancing toward 2027 top-line readouts.

Supernus generates revenue through (1) direct U.S. product sales via its specialty sales force, with four designated growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—representing approximately 76% of total revenue; (2) collaboration and milestone revenue from the Biogen partnership for ZURZUVAE; and (3) out-licensing royalties for international territories. FY2025 revenue was $719M with 40% growth in the four-product growth franchise, and management is guiding FY2026 revenue of $840–870M (17–21% growth). Supernus operates debt-free with $384M in cash and a market capitalization of approximately $2.53–2.90B.

Short descriptiontext

Supernus Pharmaceuticals (NASDAQ: SUPN) is a Rockville, MD-based specialty biopharmaceutical company that develops and commercializes branded prescription drugs for central nervous system diseases—including ADHD, Parkinson's, epilepsy, migraine, and postpartum depression—sold primarily through U.S. specialty sales forces to neurologists and psychiatrists.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersRockville, United States
HQ citystring
Rockville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS pharmaceuticals, central nervous system therapeutics, specialty biopharmaceutical drugs, neurology and psychiatry treatments, proprietary drug delivery
Product category
Specialty CNS Pharmaceuticals
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product sales (commercial CNS portfolio)
TypeHardware Sales
Description

Direct sales of marketed CNS products (Qelbree, Trokendi XR, Oxtellar XR, GOCOVRI, ONAPGO, Apokyn, Myobloc, Xadago) through US specialty sales forces; Q1 2026 Qelbree sales of $78M, GOCOVRI $35.2M.

supernus.com
2Collaboration revenues (ZURZUVAE with Biogen)
TypeLicensing Royalties
Description

Collaboration revenue from Biogen partnership for ZURZUVAE (zuranolone), including $27.6M in Q1 2026 and $15M regulatory milestone in Q4 2025.

fool.com
3International licensing (out-licensing)
TypeLicensing Royalties
Description

Licensing of products to other pharmaceutical companies for commercialization outside the United States through strategic collaborations.

supernus.com
4Specialty pharmacy / HCP-channel distribution
TypeManaged Services
Description

Distribution of branded CNS therapies through healthcare providers, specialty pharmacies, and HUB partners with patient access programs.

supernus.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure
Pricing details1 tier
1Not publicly disclosed on company website
ModelOther
Notes

Supernus publishes state-mandated cost disclosures (Qelbree, Onapgo, Gocovri, Apokyn, Myobloc, Oxtellar, Trokendi, Xadago) rather than a public list price. Drug acquisition cost varies by state and channel.

supernus.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 9 records shown
1Qelbree
Description

Treatment for Attention Deficit/Hyperactivity Disorder (ADHD)

supernus.com
+8 more records
Core offering1 text field

Supernus Pharmaceuticals develops and commercializes a portfolio of FDA-approved branded central nervous system (CNS) prescription drugs across ADHD, Parkinson's disease, epilepsy, migraine, postpartum depression, and cervical dystonia, supported by a pipeline of investigational candidates. Its current commercial portfolio includes nine marketed products (Qelbree, Onapgo, Gocovri, Zurzuvae, Apokyn, Myobloc, Oxtellar XR, Trokendi XR, Xadago) built largely on proprietary drug delivery technology, with products sold in the United States through dedicated specialty sales forces and abroad via licensing partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 40% revenue growth across four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) representing 76% of 2025 total revenues
+4 more records
Product overview1 text field

Supernus Pharmaceuticals operates as a specialty biopharmaceutical company with a diverse, franchise-style CNS pharmaceutical portfolio rather than a unified software platform. Its nine marketed products are organized around five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, developed in collaboration with Biogen), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia / sialorrhea (Myobloc). Four of these — Qelbree, GocOVRI, ZURZUVAE, and ONAPGO — are designated as Supernus's growth products and accounted for ~76% of Q4 2025 revenues, while Oxtellar XR, Trokendi XR, Myobloc, Apokyn, and Xadago are legacy products (Trokendi XR and Oxtellar XR face loss of exclusivity). The portfolio was assembled through internal R&D using Supernus's proprietary drug delivery technologies — which were also used to develop Adderall XR, Intuniv, and Mydayis for Shire (now Takeda), and Orenitram for United Therapeutics Corporation — supplemented by the 2021 Adamas Pharmaceuticals acquisition (adding GOCOVRI) and the 2025 Sage Therapeutics acquisition (adding ZURZUVAE). The portfolio is extended by an internal pipeline that includes SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy, with Phase 2b data readouts targeted for 2027. Commercial operations in the United States are executed through Supernus's own specialty sales forces, while international commercialization is pursued via strategic collaborations.

Product and service9 records
1Qelbree (viloxazine extended-release)
CategoryCore proprietary CNS product (ADHD)
Description

Supernus's proprietary non-stimulant extended-release treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric and adult patients; one of the company's four key growth products.

2Onapgo (apomorphine subcutaneous infusion)
CategoryParkinson's disease therapy
Description

Continuous subcutaneous apomorphine infusion therapy for Parkinson's disease; recently launched growth product in Supernus's Parkinson's franchise.

3Gocovri (extended-release amantadine)
CategoryParkinson's disease therapy
Description

Extended-release amantadine product for the treatment of dyskinesia in Parkinson's disease; obtained via the 2021 Adamas Pharmaceuticals acquisition.

4Zurzuvae (zuranolone)
CategoryPostpartum depression therapy
Description

First FDA-approved oral 14-day treatment for postpartum depression; obtained via the 2025 Sage Therapeutics acquisition and commercialized in collaboration with Biogen.

5Apokyn (apomorphine injection)
CategoryParkinson's disease therapy
Description

Apomorphine injection for the acute, intermittent treatment of hypomobility, 'off' episodes associated with advanced Parkinson's disease; part of Supernus's Parkinson's portfolio.

6Myobloc (rimabotulinumtoxinB injection)
CategoryCervical dystonia / sialorrhea therapy
Description

Injectable rimabotulinumtoxinB for the treatment of cervical dystonia and sialorrhea; part of Supernus's neurology portfolio and accompanied by a boxed warning.

7Oxtellar XR (extended-release oxcarbazepine)
CategoryEpilepsy therapy
Description

Extended-release oxcarbazepine for the treatment of partial-onset seizures in epilepsy; Supernus's first internally developed CNS product utilizing its proprietary drug delivery technology.

8Trokendi XR (extended-release topiramate)
CategoryEpilepsy / migraine therapy
Description

Extended-release topiramate for epilepsy and migraine prevention; built on Supernus's proprietary drug delivery technology; a legacy product now facing loss of exclusivity.

9Xadago (safinamide)
CategoryParkinson's disease therapy
Description

Safinamide adjunct therapy for Parkinson's disease patients experiencing 'off' episodes; rounds out Supernus's Parkinson's franchise alongside Onapgo, Gocovri, and Apokyn.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeGTM or Marketing PartnerAnnounced on2026-06-17
Description

MERGE was selected as Supernus's expanded Agency of Record (AOR), extending a seven-year partnership that now unifies Supernus' digital marketing and technology platforms under a single agreement. MERGE assumes leadership of Supernus' full digital ecosystem including website development, CRM operations, and omnichannel marketing strategy. Coverage spans QELBREE (ADHD) and the Parkinson's disease portfolio (APOKYN, GOCOVRI, ONAPGO). MERGE's AI-first approach delivers hyper-personalized, compliant digital interactions across multiple sales forces.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Supernus Pharmaceuticals Inc entered into an asset purchase agreement with Navitor on April 1, 2026. Supernus CEO Jack Khattar also serves on the board of directors of Navitor Pharmaceuticals, LLC.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

Supernus completed the acquisition of Sage Therapeutics in July 2025, adding the FDA-approved product ZURZUVAE (zuranolone) for postpartum depression to its CNS portfolio. The deal was valued at approximately $561-$795 million (upfront cash + contingent value rights based on sales milestones). Expected to be accretive in 2026 with cost synergies expected to reach $200 million annually.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-31
Description

Strategic collaboration with Biogen for the commercialization of ZURZUVAE (zuranolone), the first FDA-approved oral treatment for postpartum depression. Supernus records collaboration revenue from this partnership (e.g., $27.6M in Q1 2026, $15M regulatory milestone in Q4 2025). Biogen received Health Canada authorization for ZURZUVAE in December 2025.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-11-24
Description

Supernus completed the acquisition of Adamas Pharmaceuticals on November 24, 2021, including its portfolio of Parkinson's disease treatments GOCOVRI and Osmolex ER. The deal involved a cash offer plus contingent value rights based on milestones for GOCOVRI sales. Approximately 77.3% of Adamas shares were tendered. The deal significantly diversified Supernus's revenue base and was projected to be accretive in 2022.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified global pharma with CNS-adjacent assets and historical CNS franchises; relevant as a potential acquirer and competitive benchmark for the broader CNS competitive environment facing Supernus.

TypeBroad incumbent
Description

Global biopharma with a significant CNS franchise (epilepsy with Vimpat/Briviact, Parkinson's with Rytary) and immunology; broader portfolio than Supernus but a meaningful comparator in CNS specialty commercialization.

TypeDirect peer
Description

CNS-focused biopharma commercializing Auvelity (depression) and other CNS therapies; highly comparable in target indications (depression), public-company CNS specialty profile, and growth-stage commercial ramp.

4H. Lundbeck A/S
TypeBroad incumbent
Description

Established global CNS specialty pharma with franchises in depression, migraine, and Parkinson's disease; broader portfolio and geographic reach than Supernus but directly comparable CNS therapeutic areas.

TypeOthers
Description

CNS biopharma and developer of ZURZUVAE (postpartum depression) acquired by Supernus in 2025; no longer an independent peer but historically the most directly comparable competitor in the PPD space and now integrated into Supernus's portfolio.

TypeDirect peer
Description

Neurology/CNS specialty biopharma with Ingrezza (movement disorders) and a broad CNS pipeline; comparable in CNS focus and franchise-style product portfolio, though larger and more diversified than Supernus.

TypeBroad incumbent
Description

Large generic and specialty pharma with a CNS franchise (Austedo for Huntington's/chorea, Ajovy for migraine); not a pure CNS play but a broad incumbent competing in Supernus's therapeutic neighborhoods.

TypeDirect peer
Description

Specialty CNS biopharma focused on Korlym (Cushing's) and oncology-adjacent CNS indications with a small commercial footprint and proprietary drug platform; similar specialty-CNS business model and target HCP channels.

TypeDirect peer
Description

Specialty CNS biopharma with Nuplazid (Parkinson's disease psychosis) and a pipeline in CNS/neuropsychiatry; directly comparable to Supernus in CNS focus, product-portfolio approach, and US specialty sales force model.

TypeDirect peer
Description

Specialty CNS biopharma with overlapping therapeutic areas including epilepsy (Xywav, Epidiolex) and psychiatry, comparable in size, public-company profile, and specialty sales force GTM motion to Supernus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance10 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Supernus Pharmaceuticals

Specialty CNS Pharmaceuticalssupernus.com

Supernus Pharmaceuticals (NASDAQ: SUPN) is a Rockville, MD-based specialty biopharmaceutical company that develops and commercializes branded prescription drugs for central nervous system diseases—including ADHD, Parkinson's, epilepsy, migraine, and postpartum depression—sold primarily through U.S. specialty sales forces to neurologists and psychiatrists.

What Supernus Pharmaceuticals does

Supernus Pharmaceuticals, Inc. is a publicly traded specialty biopharmaceutical company (NASDAQ: SUPN) headquartered in Rockville, Maryland, with more than 30 years of experience developing and commercializing treatments for central nervous system (CNS) diseases. The company develops, manufactures, and markets nine branded prescription products spanning five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, via Biogen collaboration), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia/sialorrhea (Myobloc). It sells primarily to U.S. specialty prescribers—neurologists, psychiatrists, and movement-disorder specialists—through dedicated specialty sales forces, while out-licensing international commercialization to other pharmaceutical partners.

The product franchise is anchored by a proprietary drug delivery and formulation technology platform that has produced ten marketed products, including own-brand launches (Qelbree, Trokendi XR, Oxtellar XR) and products developed for Shire/Takeda (Adderall XR, Intuniv, Mydayis) and United Therapeutics (Orenitram). Supernus has materially supplemented internal R&D through two acquisitions: Adamas Pharmaceuticals in November 2021 (~$450M) added GOCOVRI and Osmolex ER, and Sage Therapeutics in July 2025 (~$561–795M) added ZURZUVAE. Two Phase 2 pipeline candidates—SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy—are advancing toward 2027 top-line readouts.

Supernus generates revenue through (1) direct U.S. product sales via its specialty sales force, with four designated growth products—Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO—representing approximately 76% of total revenue; (2) collaboration and milestone revenue from the Biogen partnership for ZURZUVAE; and (3) out-licensing royalties for international territories. FY2025 revenue was $719M with 40% growth in the four-product growth franchise, and management is guiding FY2026 revenue of $840–870M (17–21% growth). Supernus operates debt-free with $384M in cash and a market capitalization of approximately $2.53–2.90B.

Supernus Pharmaceuticals firmographics

Firmographics
Name
Supernus Pharmaceuticals
Legal name
Supernus Pharmaceuticals, Inc.
Website
https://supernus.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Supernus Pharmaceuticals (NASDAQ: SUPN) is a Rockville, MD-based specialty biopharmaceutical company that develops and commercializes branded prescription drugs for central nervous system diseases—including ADHD, Parkinson's, epilepsy, migraine, and postpartum depression—sold primarily through U.S. specialty sales forces to neurologists and psychiatrists.
Ownership category
akta.pro rank

Where Supernus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Rockville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Supernus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

  1. Product sales (commercial CNS portfolio): Direct sales of marketed CNS products (Qelbree, Trokendi XR, Oxtellar XR, GOCOVRI, ONAPGO, Apokyn, Myobloc, Xadago) through US specialty sales forces; Q1 2026 Qelbree sales of $78M, GOCOVRI $35.2M.
  2. Collaboration revenues (ZURZUVAE with Biogen): Collaboration revenue from Biogen partnership for ZURZUVAE (zuranolone), including $27.6M in Q1 2026 and $15M regulatory milestone in Q4 2025.
  3. International licensing (out-licensing): Licensing of products to other pharmaceutical companies for commercialization outside the United States through strategic collaborations.
  4. Specialty pharmacy / HCP-channel distribution: Distribution of branded CNS therapies through healthcare providers, specialty pharmacies, and HUB partners with patient access programs.

Pricing tiers

ModelBillingPrice
Other—Not publicly disclosed on company website

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

Supernus Pharmaceuticals product offering

Product offering

Core offering

Supernus Pharmaceuticals develops and commercializes a portfolio of FDA-approved branded central nervous system (CNS) prescription drugs across ADHD, Parkinson's disease, epilepsy, migraine, postpartum depression, and cervical dystonia, supported by a pipeline of investigational candidates. Its current commercial portfolio includes nine marketed products (Qelbree, Onapgo, Gocovri, Zurzuvae, Apokyn, Myobloc, Oxtellar XR, Trokendi XR, Xadago) built largely on proprietary drug delivery technology, with products sold in the United States through dedicated specialty sales forces and abroad via licensing partnerships.

Product overview

Supernus Pharmaceuticals operates as a specialty biopharmaceutical company with a diverse, franchise-style CNS pharmaceutical portfolio rather than a unified software platform. Its nine marketed products are organized around five therapeutic areas: ADHD (Qelbree), Parkinson's disease (Onapgo, Gocovri, Apokyn, Xadago), postpartum depression (Zurzuvae, developed in collaboration with Biogen), epilepsy and migraine (Trokendi XR, Oxtellar XR), and cervical dystonia / sialorrhea (Myobloc). Four of these — Qelbree, GocOVRI, ZURZUVAE, and ONAPGO — are designated as Supernus's growth products and accounted for ~76% of Q4 2025 revenues, while Oxtellar XR, Trokendi XR, Myobloc, Apokyn, and Xadago are legacy products (Trokendi XR and Oxtellar XR face loss of exclusivity). The portfolio was assembled through internal R&D using Supernus's proprietary drug delivery technologies — which were also used to develop Adderall XR, Intuniv, and Mydayis for Shire (now Takeda), and Orenitram for United Therapeutics Corporation — supplemented by the 2021 Adamas Pharmaceuticals acquisition (adding GOCOVRI) and the 2025 Sage Therapeutics acquisition (adding ZURZUVAE). The portfolio is extended by an internal pipeline that includes SPN-820/821 for treatment-resistant depression and SPN-817 for severe epilepsy, with Phase 2b data readouts targeted for 2027. Commercial operations in the United States are executed through Supernus's own specialty sales forces, while international commercialization is pursued via strategic collaborations.

Differentiator

Problem solved

Functional benefit

Brands

  • Qelbree: Treatment for Attention Deficit/Hyperactivity Disorder (ADHD)
  • Onapgo
  • Gocovri
  • Zurzuvae
  • Apokyn
  • Myobloc
  • Oxtellar XR
  • Trokendi XR
  • Xadago

Products and services

  • Qelbree (viloxazine extended-release) Supernus's proprietary non-stimulant extended-release treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in pediatric and adult patients; one of the company's four key growth products.
  • Onapgo (apomorphine subcutaneous infusion) Continuous subcutaneous apomorphine infusion therapy for Parkinson's disease; recently launched growth product in Supernus's Parkinson's franchise.
  • Gocovri (extended-release amantadine) Extended-release amantadine product for the treatment of dyskinesia in Parkinson's disease; obtained via the 2021 Adamas Pharmaceuticals acquisition.
  • Zurzuvae (zuranolone) First FDA-approved oral 14-day treatment for postpartum depression; obtained via the 2025 Sage Therapeutics acquisition and commercialized in collaboration with Biogen.
  • Apokyn (apomorphine injection) Apomorphine injection for the acute, intermittent treatment of hypomobility, 'off' episodes associated with advanced Parkinson's disease; part of Supernus's Parkinson's portfolio.
  • Myobloc (rimabotulinumtoxinB injection) Injectable rimabotulinumtoxinB for the treatment of cervical dystonia and sialorrhea; part of Supernus's neurology portfolio and accompanied by a boxed warning.
  • Oxtellar XR (extended-release oxcarbazepine) Extended-release oxcarbazepine for the treatment of partial-onset seizures in epilepsy; Supernus's first internally developed CNS product utilizing its proprietary drug delivery technology.
  • Trokendi XR (extended-release topiramate) Extended-release topiramate for epilepsy and migraine prevention; built on Supernus's proprietary drug delivery technology; a legacy product now facing loss of exclusivity.
  • Xadago (safinamide) Safinamide adjunct therapy for Parkinson's disease patients experiencing 'off' episodes; rounds out Supernus's Parkinson's franchise alongside Onapgo, Gocovri, and Apokyn.

Quantifiable outcome

  • 40% revenue growth across four growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) representing 76% of 2025 total revenues
  • +4 more outcomes

Companies that use Supernus Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Supernus Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Supernus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major and minor.

  • MERGEmajorGTM or Marketing Partner · 17 June 2026MERGE was selected as Supernus's expanded Agency of Record (AOR), extending a seven-year partnership that now unifies Supernus' digital marketing and technology platforms under a single agreement. MERGE assumes leadership of Supernus' full digital ecosystem including website development, CRM operations, and omnichannel marketing strategy. Coverage spans QELBREE (ADHD) and the Parkinson's disease portfolio (APOKYN, GOCOVRI, ONAPGO). MERGE's AI-first approach delivers hyper-personalized, compliant digital interactions across multiple sales forces.
  • NavitorminorStrategic or Co-development Partner · 1 April 2026Supernus Pharmaceuticals Inc entered into an asset purchase agreement with Navitor on April 1, 2026. Supernus CEO Jack Khattar also serves on the board of directors of Navitor Pharmaceuticals, LLC.
  • Sage TherapeuticsmajorStrategic or Co-development Partner · 31 July 2025Supernus completed the acquisition of Sage Therapeutics in July 2025, adding the FDA-approved product ZURZUVAE (zuranolone) for postpartum depression to its CNS portfolio. The deal was valued at approximately $561-$795 million (upfront cash + contingent value rights based on sales milestones). Expected to be accretive in 2026 with cost synergies expected to reach $200 million annually.
  • BiogenmajorStrategic or Co-development Partner · 31 July 2025Strategic collaboration with Biogen for the commercialization of ZURZUVAE (zuranolone), the first FDA-approved oral treatment for postpartum depression. Supernus records collaboration revenue from this partnership (e.g., $27.6M in Q1 2026, $15M regulatory milestone in Q4 2025). Biogen received Health Canada authorization for ZURZUVAE in December 2025.
  • Adamas PharmaceuticalsmajorStrategic or Co-development Partner · 24 November 2021Supernus completed the acquisition of Adamas Pharmaceuticals on November 24, 2021, including its portfolio of Parkinson's disease treatments GOCOVRI and Osmolex ER. The deal involved a cash offer plus contingent value rights based on milestones for GOCOVRI sales. Approximately 77.3% of Adamas shares were tendered. The deal significantly diversified Supernus's revenue base and was projected to be accretive in 2022.

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Supernus Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Pfizer: Diversified global pharma with CNS-adjacent assets and historical CNS franchises; relevant as a potential acquirer and competitive benchmark for the broader CNS competitive environment facing Supernus.
  • UCB: Global biopharma with a significant CNS franchise (epilepsy with Vimpat/Briviact, Parkinson's with Rytary) and immunology; broader portfolio than Supernus but a meaningful comparator in CNS specialty commercialization.
  • H. Lundbeck A/S: Established global CNS specialty pharma with franchises in depression, migraine, and Parkinson's disease; broader portfolio and geographic reach than Supernus but directly comparable CNS therapeutic areas.
  • Teva Pharmaceutical Industries: Large generic and specialty pharma with a CNS franchise (Austedo for Huntington's/chorea, Ajovy for migraine); not a pure CNS play but a broad incumbent competing in Supernus's therapeutic neighborhoods.

Direct peers

  • Axsome Therapeutics: CNS-focused biopharma commercializing Auvelity (depression) and other CNS therapies; highly comparable in target indications (depression), public-company CNS specialty profile, and growth-stage commercial ramp.
  • Neurocrine Biosciences: Neurology/CNS specialty biopharma with Ingrezza (movement disorders) and a broad CNS pipeline; comparable in CNS focus and franchise-style product portfolio, though larger and more diversified than Supernus.
  • Corcept Therapeutics: Specialty CNS biopharma focused on Korlym (Cushing's) and oncology-adjacent CNS indications with a small commercial footprint and proprietary drug platform; similar specialty-CNS business model and target HCP channels.
  • Acadia Pharmaceuticals: Specialty CNS biopharma with Nuplazid (Parkinson's disease psychosis) and a pipeline in CNS/neuropsychiatry; directly comparable to Supernus in CNS focus, product-portfolio approach, and US specialty sales force model.
  • Jazz Pharmaceuticals: Specialty CNS biopharma with overlapping therapeutic areas including epilepsy (Xywav, Epidiolex) and psychiatry, comparable in size, public-company profile, and specialty sales force GTM motion to Supernus.

Others

  • Sage Therapeutics: CNS biopharma and developer of ZURZUVAE (postpartum depression) acquired by Supernus in 2025; no longer an independent peer but historically the most directly comparable competitor in the PPD space and now integrated into Supernus's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Supernus Pharmaceuticals social profiles

Digital presence

Supernus Pharmaceuticals compliance and trust

Trust signal

Compliance10 records

Supernus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Supernus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles16 records

Supernus Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Supernus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Supernus Pharmaceuticals M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Supernus Pharmaceuticals

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals develops and commercializes a portfolio of FDA-approved branded central nervous system (CNS) prescription drugs across ADHD, Parkinson's disease, epilepsy, migraine, postpartum depression, and cervical dystonia, supported by a pipeline of investigational candidates. Its current commercial portfolio includes nine marketed products (Qelbree, Onapgo, Gocovri, Zurzuvae, Apokyn, Myobloc, Oxtellar XR, Trokendi XR, Xadago) built largely on proprietary drug delivery technology, with products sold in the United States through dedicated specialty sales forces and abroad via licensing partnerships.

Is Supernus Pharmaceuticals a public or private company?

Supernus Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Supernus Pharmaceuticals founded?

Supernus Pharmaceuticals was founded in 2005. It employs 501 to 1,000 people.

Where is Supernus Pharmaceuticals based?

Supernus Pharmaceuticals is headquartered in Rockville, United States, in the North America region.

How does Supernus Pharmaceuticals make money?

Four revenue lines are on record. Product sales (commercial CNS portfolio) is the primary driver. The others are collaboration revenues (ZURZUVAE with Biogen), international licensing (out-licensing) and specialty pharmacy / HCP-channel distribution.

Who are Supernus Pharmaceuticals's main competitors?

Broad incumbents on record are Pfizer, UCB, H. Lundbeck A/S and Teva Pharmaceutical Industries. Direct peers are Axsome Therapeutics, Neurocrine Biosciences, Corcept Therapeutics, Acadia Pharmaceuticals and Jazz Pharmaceuticals. Sage Therapeutics is listed as an others.

Does Supernus Pharmaceuticals have an API?

No public API is recorded for Supernus Pharmaceuticals.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooDoes Supernus Pharmaceuticals (SUPN) Still Trade Below Fair Value On Sales?Supernus Pharmaceuticals has gained 75.7% over three years, though its stock is down year to date. Its P/S ratio of 2.8x is below the industry average of 4.1x and peer group of 6.3x, suggesting undervaluation. The company's neurology-focused sales durability could justify closing the gap.TradingViewSupernus Pharmaceuticals: Post-merger priorities center on CNS growth products, pipeline investment and selective business developmentThe completed Indivior merger creates a ~$2.2B revenue business with leverage below 1x, focusing on growing key CNS products, advancing pipeline assets, and pursuing deals. Updates on Sublocade, Onapgo, and Qelbree outline growth drivers and 2027 considerations.American Banking and Market NewsSupernus Pharmaceuticals, Inc. $SUPN Shares Newly Acquired by CenterBook Partners LPCenterBook Partners LP acquired a new stake in Supernus Pharmaceuticals during Q3, buying 20,350 shares valued at about $876,000. Supernus reported Q3 EPS of $0.35, missing the $0.49 consensus, while revenue rose 18% to $208.60 million. Analysts have a consensus target price of $60.20.YahooSupernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in LondonSupernus CEO Jack A. Khattar will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in London on Nov 16, 2026. The company's commercial portfolio includes treatments for CNS conditions such as opioid use disorder, ADHD, and Parkinson's disease. A live webcast and archived replay will be available on the company's website.YahooSupernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run ContinuesSupernus shares trade at $27.62 after a pullback, having gained 127.5% over five years. Its P/E of 12.7x is below the sector average of 15.2x, and the planned merger with Indivior may support higher future profitability. The stock's valuation remains undervalued on a Fair Ratio basis.Investing.comBofA initiates Supernus Pharmaceuticals stock at buy on merger scaleBofA Securities initiated a buy rating on Supernus Pharmaceuticals with a $47 price target, implying about 80% upside from the current $26.16. The target follows the merger with Indivior, which BofA previously covered, and expects legacy Supernus to drive two-thirds of revenue growth into the early 2030s. Revenue grew 16% to $1.37 billion over the past year.TradingViewPiper Sandler reinstates coverage of Supernus at Overweight, sets price target at $47Piper Sandler reinstated coverage of Supernus at Overweight and set a price target of $47. The target implies an upside of 12.1% from the Oct 30 close of $41.92.YahooWhat Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?Supernus Pharmaceuticals completed its merger with Indivior, delisting from Nasdaq and rolling equity into the combined entity. The deal consolidates governance and targets $125 million in annual cost synergies. Integration progress and synergy delivery in 2027 results are key checkpoints for investors.MarketScreenerSupernus Pharmaceuticals, Inc.(NasdaqGM: SUPN) dropped from S&P 1000Supernus Pharmaceuticals dropped from the S&P 1000 and S&P 600 indices on November 2, 2026. The stock closed at $41.92, down 15.65% from the previous day's close. The company's composite ratings are based on valuation, EPS revisions, and visibility.MarketScreenerSupernus Pharmaceuticals, Inc.(NasdaqGM: SUPN) dropped from S&P Pharmaceuticals Select Industry IndexSupernus Pharmaceuticals dropped from the S&P Pharmaceuticals Select Industry Index, as well as the S&P Composite 1500 and S&P 600, on November 2, 2026. The company's stock closed at $41.92, down 15.65% from the previous day's close.